231 related articles for article (PubMed ID: 36314547)
1. New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.
Garcia-Prats AJ; Starke JR; Waning B; Kaiser B; Seddon JA
J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S101-S109. PubMed ID: 36314547
[TBL] [Abstract][Full Text] [Related]
2. Shortened tuberculosis treatment regimens: what is new?
Silva DR; Mello FCQ; Migliori GB
J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
[TBL] [Abstract][Full Text] [Related]
3. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
Aguilar Diaz JM; Abulfathi AA; Te Brake LH; van Ingen J; Kuipers S; Magis-Escurra C; Raaijmakers J; Svensson EM; Boeree MJ
Respiration; 2023; 102(2):83-100. PubMed ID: 36516792
[TBL] [Abstract][Full Text] [Related]
4. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
[TBL] [Abstract][Full Text] [Related]
5. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
[TBL] [Abstract][Full Text] [Related]
6. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
Harausz EP; Garcia-Prats AJ; Seddon JA; Schaaf HS; Hesseling AC; Achar J; Bernheimer J; Cruz AT; D'Ambrosio L; Detjen A; Graham SM; Hughes J; Jonckheere S; Marais BJ; Migliori GB; McKenna L; Skrahina A; Tadolini M; Wilson P; Furin J;
Am J Respir Crit Care Med; 2017 May; 195(10):1300-1310. PubMed ID: 27854508
[TBL] [Abstract][Full Text] [Related]
7. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
8. New drugs and perspectives for new anti-tuberculosis regimens.
Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
[TBL] [Abstract][Full Text] [Related]
9. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
10. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
[TBL] [Abstract][Full Text] [Related]
12. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
[TBL] [Abstract][Full Text] [Related]
13. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
[TBL] [Abstract][Full Text] [Related]
14. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
16. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
Kengo A; Nabeemeeah F; Denti P; Sabet R; Okyere-Manu G; Abraham P; Weisner L; Mosala MH; Tshabalala S; Scholefield J; Resendiz-Galvan JE; Martinson NA; Variava E
Antimicrob Agents Chemother; 2024 May; 68(5):e0158323. PubMed ID: 38597667
[TBL] [Abstract][Full Text] [Related]
17. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
18. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]